Upfront, comprehensive genetic testing in advanced lung cancer is cost-effective

(American Society of Clinical Oncology) An economic model comparing different types of genetic testing in metastatic non-small-cell lung cancer (NSCLC) found that using next-generation sequencing (NGS) to test for all known lung cancer-related gene changes at the time of diagnosis was more cost-effective and faster than testing one or a limited number of genes at a time.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news